: Aurobindo Pharma Monday said its consolidated net profit after its Joint Venture share and minority interest for the quarter ended September 30 was down by 21.7 per cent to Rs 611.40 crore against Rs 781.10 crore in the second quarter of the last fiscal.
A company press release said the drug maker clocked Rs 4,751.40 crore revenues from operations, up 7.1 per cent when compared to Rs 4,435.90 crore during the same quarter in FY18.
N Govindarajan, Managing Director of the company said: "We have delivered a healthy quarter in terms of both financial performance and developments in differentiated portfolio.
Our revenues increased by seven per cent YoY, EBITDA ( earnings before interest, tax, depreciation and amortisation) and margin for the quarter was at 21.6 per cent and net profit after JV share and minority interest was at Rs 611.40 crore."